A Post-Doctoral Research Fellowship has been funded under the European Union’s INTERREG VA Programme for a pioneering cross-border research project, designed to better understand and alleviate the impact of Chronic Obstructive Airways Disease (COPD). The BREATH project involves a strong cross-border partnership between the Smooth Muscle Research Centre (Dundalk Institute of Technology; DkIT), the School […]
Aaron joined Almac Discovery in 2016 and has responsibility for translational research activities including key external research collaborations. Aaron has over 20 years of experience in preclinical oncology and left Mission Therapeutics, where he was Head of Pharmacology for the deubiquitylating enzyme (DUB) specialist, to join Discovery. Aaron has also previously worked for PRECOS, a […]
Company Overview Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex-Pharma and Biotech), with a track record in delivering successful clinical programmes. Almac Discovery utilises its capabilities and expertise to discover and develop NCEs and Novel Protein Therapeutics through […]
ALM 201 Background ALM201 is a novel first-in-class synthetic peptide that is based on the naturally-occurring protein, FK506 binding protein-like (FKBPL). This protein has been reported to bind to the cell surface receptor CD44 and have anti-angiogenic activity in preclinical tumour models (Valentine et al., 2011; internal unpublished results). An ALM201 peptide derivative has been reported […]
Are you passionate about working in a highly exciting and research-driven drug discovery company? Almac Discovery is an independent drug discovery company dedicated to the development of novel and innovative therapeutics. Our multidisciplinary team of scientists use cutting edge research techniques to develop First in Class preclinical stage assets which are then licenced to pharmaceutical […]
Genentech In June 2015 Almac Discovery, entered into a Research and Licensing agreement with Genentech, a member of the Roche Group to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target. Under the terms of the agreement, Almac Discovery received an upfront payment of $14.5 million and were eligible to receive […]
Company Overview Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. We are led by an experienced team (ex-Pharma and Biotech), with a track record in delivering successful clinical programmes. We utilise our capabilities and expertise to discover and develop NCEs and Novel Protein Therapeutics through to […]
Graham joined Almac from the acquisition of Albachem and subsequently joined Almac Discovery to bring expertise in peptide and protein chemistry. Graham has responsibility for the technical management of Discovery’s Protein Drug Conjugate key research focus within Almac Discovery and was important in the discovery of the peptide clinical candidate, ALM201.
Lisa joined Almac Discovery in 2016 and has responsibility for the project management of preclinical and clinical programmes. She has 10 years of mainly oncology experience gained across both drug development and stratified medicine.
Almac Discovery Key Research Ubiquitin Specific Proteases Deubiquitinating enzymes (DUBs) and their subset ubiquitin specific proteases (USP’s) hold the promise of producing many new drugs across a wide range of indications. Until now this target class has remained intractable, but because of Almac Discovery’s unique knowledge base within this area we are committed to change that. […]
Our vision is to be widely recognised and acknowledged within the global biopharmaceutical community as an industry-leading discoverer and developer of innovative, first-in-class, drug molecules. By fully utilising the expertise and knowledge of our team to address the significant hurdles inherent in drug discovery, we are driven to make fundamental contributions to the development and […]
We are a research-driven biotech company dedicated to the discovery of first-in-class therapies addressing unmet needs. Our platforms and portfolio deliver NCEs and protein therapeutics against novel targets of relevance in oncology and neurodegeneration.
Background With the increasing number of antibody-drug conjugate approvals, including for use in the adjuvant setting (Kadcyla®), and with a growing number of ADCs entering clinical trials, the targeted delivery of cytotoxic agents to cancer cells is proving to be a powerful approach for the treatment of both haematological malignancies and solid tumours. Whilst efforts […]
Stephen is a member of the Almac Group Executive Management and President and Managing Director of both Almac Discovery and Almac Sciences. He was instrumental in establishing Almac Discovery and has had overall responsibility for strategic, financial and operational leadership ever since.
Tim joined Almac Sciences in 2006 as Vice President of Research and Development before moving to Almac Discovery on its establishment in 2008: an initiative he had played a key role in planning and championing. He now has responsibility for all R&D activities and for coordinating the relationship with Queen’s University which, most recently, is […]
Background The development of drugs such as Velcade®, Revlimid® and Kyprolis® has validated the ubiquitin-proteasome system as an attractive arena for drug discovery, as well as revolutionised the treatment of previously intractable conditions such as multiple myeloma. Building on this success, the current interest in protein homeostasis as a therapeutic strategy has further highlighted the […]
Ubiquitin specific protease 7 (USP7) is a member of the deubiquitinating enzyme class that contains 106 representatives in human cells. USP7 removes the post-translational tag ubiquitin from several protein targets 1. USP7 best characterised role is the removal of ubiquitin from the oncogene MDM2 and thus regulating the tumour suppressor protein p53 2. It has […]
Background Many cancer treatments such as radiation, antimetabolites, alkylating agents, DNA topoisomerase inhibitors and platinum compounds damage DNA in cells. The cellular response is to arrest the cell cycle temporarily to allow DNA repair hence reducing the effects of chemotherapy. Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases and is […]
Working at Almac Discovery If you are passionate about your science and working in a driven environment dedicated to oncology and would welcome the opportunity of a friendly but challenging company we are always interested in hearing from you. Please email us at [email protected] You can view a full list of current Almac Discovery vacancies and […]
Xavier joined Almac Discovery in 2018 and is leading the biology team for the company’s small molecule discovery. He has over 18 years of industry experience and a track record in early stage discovery and development for highly innovative oncology and CNS drug target classes.